Evidence map›Paper›PMID 38580568›Full record

ReviewSeminars in nephrology2024

Pediatric Kidney Transplantation: Cancer and Cancer Risk.

Kaitlyn E Order, Nancy M Rodig

Abstract readReview
In one paragraph

Review in Seminars in nephrology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Pediatric Kidney Transplantation: A Systematic Review.Children (Basel, Switzerland) · 2026
    Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Kaitlyn E OrderDivision of Nephrology, Department of Pediatrics, Boston Children's Hospital, Boston, MA.
Nancy M RodigDivision of Nephrology, Department of Pediatrics, Boston Children's Hospital, Boston, MA. Electronic address: nancy.rodig@childrens.harvard.edu.

Funding

RESEARCH TRAINING IN PEDIATRIC NEPHROLOGYT32DK007726 · NIDDK · CHILDREN'S HOSPITAL BOSTON · PI BRISCOE, DAVID M. · 1994 to 2023
$5.9M
NIDDK NIH HHS T32 DK007726
6 · The paper itself

Abstract

Children with end-stage kidney disease (ESKD) face a lifetime of complex medical care, alternating between maintenance chronic dialysis and kidney transplantation. Kidney transplantation has emerged as the optimal treatment of ESKD for children and provides important quality of life and survival advantages. Although transplantation is the preferred therapy, lifetime exposure to immunosuppression among children with ESKD is associated with increased morbidity, including an increased risk of cancer. Following pediatric kidney transplantation, cancer events occurring during childhood or young adulthood can be divided into two broad categories: post-transplant lymphoproliferative disorders and non-lymphoproliferative solid tumors. This review provides an overview of cancer incidence, types, outcomes, and preventive strategies in this population.

Indexed as

Kidney Failure, ChronicKidney TransplantationLymphoproliferative DisordersNeoplasmsChildHumansImmunosuppression TherapyImmunosuppressive AgentsIncidencePostoperative ComplicationsRisk FactorsImmunosuppressive AgentsCancerkidney transplantpediatricpost-transplant lymphoproliferative disorder

Identifiers

PMID38580568
PMCPMC11734768

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.